Seeking Alpha

Oppenheimer reiterates a Buy on Questcor Pharmaceuticals (QCOR) following talks with U.S....

Oppenheimer reiterates a Buy on Questcor Pharmaceuticals (QCOR) following talks with U.S. nephrologists who have experience with its Acthar MS drug. The firm believes the biggest headwind facing Acthar adoption is physician awareness, which it expects will be addressed by sales force expansion and new studies. Questcor was recently hit by a weak monthly sales report for Acthar.
Comments (1)
  • Ernest P Icahn
    , contributor
    Comments (377) | Send Message
     
    According to the website expenses to be 20-25% higher in 1st & 2nd Q than was in Q4. Training new sales reps & new Docs Lupus experiments may cost up to $7,200,000 extra per Q. That can mean a loss of as much as $0.11 EPS or slowing to a 4.2% Sequential EPS Growth Rate. -Ernest
    20 Mar 2012, 02:21 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|